347 related articles for article (PubMed ID: 31548228)
1. Challenges and Promise of a Hepatitis C Virus Vaccine.
Cox AL
Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548228
[TBL] [Abstract][Full Text] [Related]
2. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
Bailey JR; Barnes E; Cox AL
Gastroenterology; 2019 Jan; 156(2):418-430. PubMed ID: 30268785
[TBL] [Abstract][Full Text] [Related]
3. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
4. [Development approaches for vaccines against hepatitis C virus infections].
Bankwitz D; Krey T; Pietschmann T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):183-191. PubMed ID: 35015104
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.
Hartlage AS; Kapoor A
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452460
[TBL] [Abstract][Full Text] [Related]
6. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
Roohvand F; Kossari N
Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
[TBL] [Abstract][Full Text] [Related]
7. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.
Wijesundara DK; Gummow J; Li Y; Yu W; Quah BJ; Ranasinghe C; Torresi J; Gowans EJ; Grubor-Bauk B
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437963
[TBL] [Abstract][Full Text] [Related]
8. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
Ahlén G; Frelin L
Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C vaccine: supply and demand.
Strickland GT; El-Kamary SS; Klenerman P; Nicosia A
Lancet Infect Dis; 2008 Jun; 8(6):379-86. PubMed ID: 18501853
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis C virus vaccine].
Wakita T
Nihon Rinsho; 2008 Oct; 66(10):1961-4. PubMed ID: 18939497
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus vaccines among people who inject drugs.
Cox AL; Thomas DL
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S46-50. PubMed ID: 23884065
[TBL] [Abstract][Full Text] [Related]
12. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
13. Ever closer to a prophylactic vaccine for HCV.
Swadling L; Klenerman P; Barnes E
Expert Opin Biol Ther; 2013 Aug; 13(8):1109-24. PubMed ID: 23651228
[TBL] [Abstract][Full Text] [Related]
14. Burden of pediatric hepatitis C.
El-Shabrawi MH; Kamal NM
World J Gastroenterol; 2013 Nov; 19(44):7880-8. PubMed ID: 24307782
[TBL] [Abstract][Full Text] [Related]
15. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
16. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
17. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.
Baumert TF; Fauvelle C; Chen DY; Lauer GM
J Hepatol; 2014 Nov; 61(1 Suppl):S34-44. PubMed ID: 25443345
[TBL] [Abstract][Full Text] [Related]
18. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME
BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.
Lange M; Fiedler M; Bankwitz D; Osburn W; Viazov S; Brovko O; Zekri AR; Khudyakov Y; Nassal M; Pumpens P; Pietschmann T; Timm J; Roggendorf M; Walker A
PLoS One; 2014; 9(7):e102235. PubMed ID: 25014219
[TBL] [Abstract][Full Text] [Related]
20. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
